Scribe Therapeutics opened trading after pricing an upsized IPO, signaling fresh investor appetite for CRISPR-based pipeline bets. The company priced 8.6 million shares at $15 each for about $129 million in gross proceeds, beginning trade on Nasdaq under ticker SCTX. The fundraising arrives as the platform’s early clinical and preclinical work for cardiovascular and metabolic diseases remains a key proof point for the genomics editing wave. Investors also appear to be rewarding the IPO debut, with shares jumping sharply on the first day of trading, according to market reports referenced in the filing coverage. For the sector, the deal underlines that CRISPR-focused companies can still attract capital even amid high clinical attrition expectations, provided the story is anchored by credible development plans and near-term milestones.